Skip to main content
OpenTrials
Completed

NCT Number: NCT00330278

Timing of Prophylactic Antibiotics for Cesarean Sections

This is a randomized, double-blinded placebo controlled trial of cefazolin timing before cesarean section fo infection prophylaxis. Subjects are randomized to cefazolin either 30 minutes prior to skin incision or at time of cord-clamping. Primary outcome is infectious morbidity including wound infections and endometritis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Pregnant 24-43 weeks gestation > 18 years old Requiring cesarean section -

Exclusion criteria

Receiving antibiotics < 18 years old Allergy to cefazolin

-

Treatment and study plan

Cefazolin

Drug

Primary outcomes

  1. Combined infectious morbidity - endometritis + wound infection

Secondary outcomes

  1. Neonatal sepsis

  2. Allergic reactions

Sponsors and collaborators

Lead sponsor

Medical University of South Carolina

Other

Registry information

Official study title

A Randomized, Double-Blind, Placebo Controlled Trial of Cefazolin Given Either 30 Minutes Prior to Cesarean Section or at Cord Clamping

Important dates

Study start
2003
Study completion
2006
First posted
May 26, 2006
Registry last updated
Sep 27, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.